2026/141: 1 T4A Junior Higher Technician
Call for applications for a T4A Junior Higher Technician position within the Department of Hematologic Oncology and Transplantation (Cellular Immunotherapy and Gene Therapy Group). Application deadline: 30 October 2026 at 3:00 p.m.
About the Unit / Research Group
The Cellular Immunotherapy and Gene Therapy Group (GITG) within the Hematology Department focuses on the study of genetically modified T cells expressing chimeric antigen receptors (CARs) and their clinical application in patients with hematological malignancies.
The GITG at IR Sant Pau is a well-established research group that develops and manufactures advanced CART therapy products for the treatment of patients with lymphoid hematological malignancies.
Our group initiated a first-in-Europe Phase I clinical trial using CART30 cells (HSP-CAR30) for patients with Hodgkin lymphoma, and the Phase II study is currently ongoing. During 2024, a second clinical trial was launched in patients with refractory B-cell lymphomas using selected memory T cells expressing CAR19 (HSP-CAR19M). Both HSP-CAR30 and HSP-CAR19M products are fully manufactured at Sant Pau by the GITG according to Good Manufacturing Practice (GMP) standards.
Current research lines focus on:
- Investigating the antitumor efficacy of memory T-cell subsets.
- Studying the antitumor efficacy of genetically modified stem memory T cells expressing CARs.
- Developing innovative fourth-generation CARs targeting antigens expressed in hematological malignancies.
- Developing academic CART immunotherapy clinical trials for patients with lymphoid malignancies.
Essential Requirements
- Minimum qualification required: Higher Education degree (Bachelor's Degree, University Diploma, or equivalent).
- Oral and written proficiency in the two official languages of Catalonia or, alternatively, the selected candidate must demonstrate, or commit to acquiring within a maximum period of one year, an adequate command of both official languages.
- Intermediate level of English.
- Intermediate level of office software tools (Excel, Word, PowerPoint, etc.).
The following will be valued
- Knowledge of immunology, immunotherapy, tumour immunology assays, and molecular biology techniques (qPCR).
- Experience in the development of CART therapies.
- Experience in flow cytometry and cell culture techniques.
Duties
- Manufacturing advanced therapy medicinal products (CART cells) in compliance with GMP standards.
- Manufacturing lentiviral vectors under GMP regulations within the Advanced Therapies Unit of IR Sant Pau (Clean Room Facility).
- Inventory control and materials management in accordance with GMP requirements.
- Drafting and preparing protocols and records associated with GMP manufacturing of lentiviral vectors and CART cells.
- Supporting quality control activities for GMP CART-cell manufacturing, including flow cytometry, cytotoxicity assays, and qPCR analyses.
- Preparing reports on incidents and non-conformities related to the assigned work environment.
- Supporting equipment control, maintenance, and calibration activities.
- Performing equipment maintenance and review tasks.
We Offer
- Permanent contract linked to the research line: “CART Therapy for Hematological Cancer.”
- Annual workload of 1,627.5 hours (37.5 hours per week).
- Salary according to the applicable collective agreement.
- Integration into the Hematologic Oncology and Transplantation Group.
Application Procedure and Deadline
Interested candidates should preferably submit their documentation in PDF format by email to the Management of the Research Institute Foundation of Hospital de la Santa Creu i Sant Pau at seleccio@recercasantpau.cat, indicating reference 2026/141.
Required documentation:
- Cover letter.
- Updated Curriculum Vitae.
- CONSENT FOR THE PROCESSING OF PERSONAL DATA
Candidates may be required by the Research Institute Foundation of Hospital de la Santa Creu i Sant Pau to provide supporting documentation for the qualifications and achievements listed in their Curriculum Vitae.
The deadline for submitting applications is 30 October 2026 at 3:00 p.m.